Vu Ma

Discovery of a Covalent Inhibitor of KRAS^G12C (AMG 510) for the Treatment of Solid Tumors

Brian A. Lanman, Jennifer R. Allen, John G. Allen et al. · Journal of Medicinal Chemistry · 2019 · 722 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Discovery of <i>N</i>-(1-Acryloylazetidin-3-yl)-2-(1<i>H</i>-indol-1-yl)acetamides as Covalent Inhibitors of KRAS^G12C

Youngsook Shin, Joon Won Jeong, Ryan P. Wurz et al. · ACS Medicinal Chemistry Letters · 2019 · 105 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15

Two-step solution-phase synthesis of novel benzimidazoles utilizing a UDC (Ugi/de-Boc/cyclize) strategy

Paul Tempest, Vu Ma, Samuel W. Thomas et al. · Tetrahedron Letters · 2001 · 84 citations

Pharmacy, Chemistry, Medicinal Chemistry +5

MCC/S N Ar methodology. Part 1: Novel access to a range of heterocyclic cores

Paul Tempest, Vu Ma, Michael Kelly et al. · Tetrahedron Letters · 2001 · 74 citations

Natural Sciences, Chemistry, Spectroscopic Analysis +5

Novel Vanilloid Receptor-1 Antagonists:  3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic Properties

Huiling Wang, Jodie G. Katon, Balan Chenera et al. · Journal of Medicinal Chemistry · 2007 · 72 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16